Evidence map›Paper›PMID 26270561›Full record

ArticlePloS one2015

Dietary Pectin Increases Intestinal Crypt Stem Cell Survival following Radiation Injury.

Sripathi M Sureban, Randal May, Dongfeng Qu, Parthasarathy Chandrakesan, Nathaniel Weygant, Naushad Ali, Stan A Lightfoot, Kai Ding, Shahid Umar, Michael J Schlosser and 1 more

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Observational
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sripathi M SurebanDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America; Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, United States of America; The Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States of America.
Randal MayDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America; Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, United States of America.
Dongfeng QuDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.
Parthasarathy ChandrakesanDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.
Nathaniel WeygantDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.
Naushad AliDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America; The Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States of America.
Stan A LightfootDepartment of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.
Kai DingDepartment of Biostatistics and Epidemiology, College of Public Health, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.
Shahid UmarDepartment of Molecular & Integrative Physiology, The University of Kansas, Kansas City, Kansas, United States of America.
Michael J SchlosserCOARE Biotechnology Inc., Oklahoma City, Oklahoma, United States of America.
Courtney W HouchenDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America; Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, United States of America; The Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States of America.

Funding

Intestinal Stem Cell Consortium Coordinating CenterU01DK085532 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI NILAND, JOYCE CAROL · 2009 to 2018
$6.5M
Limited Competition for the Continuation of the Intestinal Stem Cell Consortium Coordinating CenterU24DK085532 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI NILAND, JOYCE CAROL · 2019 to 2023
$2.3M
Isolation and Characterization of Intestinal Stem Cells Using Novel Markers (RP)U01DK085508 · NIDDK · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HOUCHEN, COURTNEY WAYNE · 2009 to 2014
$2.0M
NIDDK NIH HHS U01 DK-085508NIDDK NIH HHS U01 DK085508NIDDK NIH HHS U01 DK085532NIDDK NIH HHS U24 DK085532
6 · The paper itself

Abstract

Gastrointestinal (GI) mucosal damage is a devastating adverse effect of radiation therapy. We have recently reported that expression of Dclk1, a Tuft cell and tumor stem cell (TSC) marker, 24h after high dose total-body gamma-IR (TBI) can be used as a surrogate marker for crypt survival. Dietary pectin has been demonstrated to possess chemopreventive properties, whereas its radioprotective property has not been studied. The aim of this study was to determine the effects of dietary pectin on ionizing radiation (IR)-induced intestinal stem cell (ISC) deletion, crypt and overall survival following lethal TBI. C57BL/6 mice received a 6% pectin diet and 0.5% pectin drinking water (pre-IR mice received pectin one week before TBI until death; post-IR mice received pectin after TBI until death). Animals were exposed to TBI (14 Gy) and euthanized at 24 and 84h post-IR to assess ISC deletion and crypt survival respectively. Animals were also subjected to overall survival studies following TBI. In pre-IR treatment group, we observed a three-fold increase in ISC/crypt survival, a two-fold increase in Dclk1+ stem cells, increased overall survival (median 10d vs. 7d), and increased expression of Dclk1, Msi1, Lgr5, Bmi1, and Notch1 (in small intestine) post-TBI in pectin treated mice compared to controls. We also observed increased survival of mice treated with pectin (post-IR) compared to controls. Dietary pectin is a radioprotective agent; prevents IR-induced deletion of potential reserve ISCs; facilitates crypt regeneration; and ultimately promotes overall survival. Given the anti-cancer activity of pectin, our data support a potential role for dietary pectin as an agent that can be administered to patients receiving radiation therapy to protect against radiation-induces mucositis.

Indexed as

AnimalsCell SurvivalDietary SupplementsDoublecortin-Like KinasesFemaleGastric MucosaGene Expression RegulationMiceMice, Inbred C57BLMucositisPectinsProtein Serine-Threonine KinasesRadiation Injuries, ExperimentalRadiation-Protective AgentsStem CellsSurvival AnalysisDclk1 protein, mouseDoublecortin-Like KinasesPectinsProtein Serine-Threonine KinasesRadiation-Protective Agents

Identifiers

PMID26270561
PMCPMC4536042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.